Reuters logo
3 个月前
BRIEF-Abbvie says investigational regimen of Glecaprevir/Pibrentasvir achieved 99 pct SVR(12) rate in chronic hepatitis C patients
2017年4月20日 / 下午12点48分 / 3 个月前

BRIEF-Abbvie says investigational regimen of Glecaprevir/Pibrentasvir achieved 99 pct SVR(12) rate in chronic hepatitis C patients

1 分钟阅读

April 20 (Reuters) - Abbvie Inc

* Abbvie's investigational, pan-genotypic, ribavirin-free regimen of Glecaprevir/Pibrentasvir (G/P) achieved 99 percent SVR(12) rate in chronic hepatitis C patients with compensated cirrhosis

* Abbvie Inc - in expedition-1 study, majority of adverse events were mild and no patients discontinued treatment due to an AE

* Abbvie Inc - most common adverse events (≥10 percent) were fatigue and headache Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below